Announcement • Jun 30
Shandong Sanyuan Biotechnology Co.,Ltd. to Report First Half, 2026 Results on Aug 28, 2026 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report first half, 2026 results on Aug 28, 2026 Reported Earnings • Apr 29
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.46 (down from CN¥0.52 in FY 2024). Revenue: CN¥649.5m (down 8.9% from FY 2024). Net income: CN¥91.4m (down 13% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue missed analyst estimates by 26%. Earnings per share (EPS) also missed analyst estimates by 43%. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year. Announcement • Apr 29
Shandong Sanyuan Biotechnology Co.,Ltd., Annual General Meeting, May 20, 2026 Shandong Sanyuan Biotechnology Co.,Ltd., Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: The Company's Meeting Room, Hangzhou, Zhejiang China Announcement • Mar 31
Shandong Sanyuan Biotechnology Co.,Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Announcement • Dec 31
Shandong Sanyuan Biotechnology Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026 Declared Dividend • Dec 29
Dividend of CN¥0.50 announced Shareholders will receive a dividend of CN¥0.50. Ex-date: 30th December 2025 Payment date: 30th December 2025 Dividend yield will be 5.6%, which is higher than the industry average of 2.2%. Sustainability & Growth Dividend is not covered by earnings (326% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 20% per year over the past 4 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 262% to bring the payout ratio under control. However, EPS has declined by 25% over the last 5 years so the company would need to reverse this trend. Reported Earnings • Oct 27
Third quarter 2025 earnings released: EPS: CN¥0.05 (vs CN¥0.14 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.05 (down from CN¥0.14 in 3Q 2024). Revenue: CN¥158.1m (up 14% from 3Q 2024). Net income: CN¥9.92m (down 66% from 3Q 2024). Profit margin: 6.3% (down from 21% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Shandong Sanyuan Biotechnology Co.,Ltd. to Report Q3, 2025 Results on Oct 27, 2025 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report Q3, 2025 results on Oct 27, 2025 New Risk • Jul 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 269% Paying a dividend despite having no free cash flows. Earnings have declined by 24% per year over the past 5 years. Announcement • Jul 02
Shandong Sanyuan Biotechnology Co.,Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Declared Dividend • May 31
Dividend of CN¥1.00 announced Shareholders will receive a dividend of CN¥1.00. Ex-date: 6th June 2025 Payment date: 6th June 2025 Dividend yield will be 4.8%, which is higher than the industry average of 2.2%. Sustainability & Growth Dividend is not covered by earnings (269% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 28% per year over the past 3 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 199% to bring the payout ratio under control. However, EPS has declined by 46% over the last 3 years so the company would need to reverse this trend. Announcement • May 30
Shandong Sanyuan Biotechnology Co.,Ltd. Announces Cash Dividend for 2024, Payable June 6, 2025 Shandong Sanyuan Biotechnology Co.,Ltd. announced 2024 final profit distribution plan to be implemented, Cash dividend per 10 shares (tax included): CNY 10.00000000. Record date: 5 June 2025, Ex-date: 6 June 2025, Payment date: 6 June 2025. Valuation Update With 7 Day Price Move • May 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥32.15, the stock trades at a trailing P/E ratio of 61.4x. Average forward P/E is 21x in the Food industry in China. Total loss to shareholders of 22% over the past three years. New Risk • May 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 136% Paying a dividend despite having no free cash flows. Earnings have declined by 24% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). New Risk • May 03
New major risk - Revenue and earnings growth Earnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 136% Paying a dividend despite having no free cash flows. Earnings have declined by 23% per year over the past 5 years. Announcement • Apr 29
Shandong Sanyuan Biotechnology Co.,Ltd., Annual General Meeting, May 26, 2025 Shandong Sanyuan Biotechnology Co.,Ltd., Annual General Meeting, May 26, 2025, at 15:00 China Standard Time. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥28.62, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 19x in the Food industry in China. Total loss to shareholders of 46% over the past three years. Announcement • Mar 31
Shandong Sanyuan Biotechnology Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 New Risk • Feb 13
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 136% The company is paying a dividend despite having no free cash flows. Dividend yield: 2.0% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • Dec 31
Shandong Sanyuan Biotechnology Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.047 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.047 in 3Q 2023). Revenue: CN¥138.1m (up 19% from 3Q 2023). Net income: CN¥29.1m (up 248% from 3Q 2023). Profit margin: 21% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Food industry in China. Announcement • Sep 30
Shandong Sanyuan Biotechnology Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥29.05, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 17x in the Food industry in China. Negligible returns to shareholders over past year. Announcement • Sep 20
Shandong Sanyuan Biotechnology Co.,Ltd. Approves Interim Cash Dividend for the Year 2024 Shandong Sanyuan Biotechnology Co.,Ltd. at its Extraordinary General Meeting held on 18 September 2024, approved interim cash dividend per ten shares (tax included) of CNY 1.50000000 for the year 2024. Reported Earnings • Aug 31
Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.12 in 2Q 2023). Revenue: CN¥185.0m (up 55% from 2Q 2023). Net income: CN¥27.7m (up 8.5% from 2Q 2023). Profit margin: 15% (down from 21% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Food industry in China. Announcement • Jul 10
Shandong Sanyuan Biotechnology Co.,Ltd. (SZSE:301206) announces an Equity Buyback for CNY 100 million worth of its shares. Shandong Sanyuan Biotechnology Co.,Ltd. (SZSE:301206) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The repurchase price will not more than CNY 35 per Share. The repurchased shares will be used for employee stock ownership plan or equity incentives. The repurchases will be funded using company's own funds. The repurchase period will be not more than 12 months. Announcement • Jun 29
Shandong Sanyuan Biotechnology Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.04 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.12 (up from CN¥0.04 in 1Q 2023). Revenue: CN¥191.9m (up 65% from 1Q 2023). Net income: CN¥24.2m (up 211% from 1Q 2023). Profit margin: 13% (up from 6.7% in 1Q 2023). The increase in margin was driven by higher revenue. Announcement • Apr 23
Shandong Sanyuan Biotechnology Co.,Ltd., Annual General Meeting, May 15, 2024 Shandong Sanyuan Biotechnology Co.,Ltd., Annual General Meeting, May 15, 2024, at 15:00 China Standard Time. Location: No. 89, Zhangfu Road, Binbei, Binzhou, Shandong China Announcement • Mar 30
Shandong Sanyuan Biotechnology Co.,Ltd. to Report Q1, 2024 Results on Apr 23, 2024 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report Q1, 2024 results on Apr 23, 2024 Announcement • Dec 30
Shandong Sanyuan Biotechnology Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report fiscal year 2023 results on Apr 23, 2024 Announcement • Sep 30
Shandong Sanyuan Biotechnology Co.,Ltd. to Report Q3, 2023 Results on Oct 27, 2023 Shandong Sanyuan Biotechnology Co.,Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023 Reported Earnings • Aug 31
Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.27 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.27 in 2Q 2022). Revenue: CN¥119.0m (down 36% from 2Q 2022). Net income: CN¥25.5m (down 55% from 2Q 2022). Profit margin: 21% (down from 31% in 2Q 2022). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥34.99, the stock trades at a trailing P/E ratio of 65.1x. Average forward P/E is 22x in the Food industry in China. Total loss to shareholders of 25% over the past year. Announcement • Jun 15
Shandong Sanyuan Biotechnology Co.,Ltd. Implements Final Profit Distribution Plan (A Shares) for 2022, Payable on 21 June 2023 Shandong Sanyuan Biotechnology Co.,Ltd. announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 7.00000000. Record date: 20 June 2023, Ex-date: 21 June 2023, Payment date: 21 June 2023. Announcement • May 20
Shandong Sanyuan Biotechnology Co.,Ltd. Approves Cash Dividend for the Year 2022 Shandong Sanyuan Biotechnology Co.,Ltd. held its Annual General Meeting of 2022 on 18 May 2023, during which it approved cash dividend of CNY 7.00000000 per ten shares (tax included) for the year 2022. Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.34 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.04 (down from CN¥0.34 in 1Q 2022). Revenue: CN¥116.3m (down 57% from 1Q 2022). Net income: CN¥7.81m (down 88% from 1Q 2022). Profit margin: 6.7% (down from 23% in 1Q 2022). The decrease in margin was driven by lower revenue. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Ning Zhu was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 26
Third quarter 2022 earnings released Third quarter 2022 results: EPS: CN¥0.15. Revenue: CN¥106.1m (down 80% from 3Q 2021). Net income: CN¥32.0m (down 84% from 3Q 2021). Profit margin: 30% (down from 38% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Food industry in China. Reported Earnings • Aug 19
Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥1.14 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.27 (down from CN¥1.14 in 2Q 2021). Revenue: CN¥184.7m (down 65% from 2Q 2021). Net income: CN¥56.4m (down 68% from 2Q 2021). Profit margin: 31% (down from 33% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 68%, compared to a 22% growth forecast for the Food industry in China. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment deteriorated over the past week After last week's 29% share price decline to CN¥46.64, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 25x in the Food industry in China. Announcement • Jun 11
Shandong Sanyuan Biotechnology Co.,Ltd. Implements Final Cash Dividend A Shares for 2021, Payable on June 17, 2022 Shandong Sanyuan Biotechnology Co.,Ltd. implemented final cash dividend A shares (tax included) of CNY 10.00000000 per ten shares for 2021, payable on June 17, 2022 with record date of June 16, 2022 and ex-date of June 17, 2022. Announcement • May 20
Shandong Sanyuan Biotechnology Co.,Ltd. Approves 2021 Profit Distribution Plan Shandong Sanyuan Biotechnology Co.,Ltd. approved 2021 profit distribution plan. The detailed profit distribution plan are as follows: 1) Cash dividend/10 shares (tax included): CNY 10.00000000 2) Bonus issue from profit (share/10 shares): none 3) Bonus issue from capital reserve (share/10 shares): 5.000000. Valuation Update With 7 Day Price Move • May 03
Investor sentiment deteriorated over the past week After last week's 23% share price decline to CN¥62.49, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 22x in the Food industry in China. Announcement • Apr 28
Shandong Sanyuan Biotechnology Co.,Ltd. Announces Final Profit Distribution Proposal for 2021 Shandong Sanyuan Biotechnology Co.,Ltd. announced on 27 April 2022 the final profit distribution proposal for 2021 as: Cash dividend/10 shares (tax included): CNY 10.00000000. Reported Earnings • Apr 28
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: CN¥0.51 (down from CN¥0.69 in 1Q 2021). Revenue: CN¥272.6m (up 3.5% from 1Q 2021). Net income: CN¥62.8m (down 9.6% from 1Q 2021). Profit margin: 23% (down from 26% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates by 36%. Over the next year, revenue is forecast to grow 41%, compared to a 18% growth forecast for the industry in China. 
